J Biol Chem, Vol. 274, Issue 31, 21937-21942, July 30, 1999
Potent Neuroprotective Properties against the Alzheimer
-Amyloid by an Endogenous Melatonin-related Indole Structure,
Indole-3-propionic Acid*
Yau-Jan
Chyan
§,
Burkhard
Poeggeler
§,
Rawhi A.
Omar¶,
Daniel G.
Chain
,
Blas
Frangione**,
Jorge
Ghiso**, and
Miguel A.
Pappolla

From the
Departments of Pathology and Neurology,
University of South Alabama, Mobile, Alabama 36617, the
¶ Department of Pathology, University of Louisville, Louisville,
Kentucky 40206, the ** Department of Pathology, New York University,
New York, New York 10016, and
Mindset Limited,
Jerusalem, Israel
 |
ABSTRACT |
Widespread cerebral deposition of a 40-43-amino
acid peptide called the amyloid
-protein (A
) in the form of
amyloid fibrils is one of the most prominent neuropathologic features
of Alzheimer's disease. Numerous studies suggest that A
is toxic to
neurons by free radical-mediated mechanisms. We have previously
reported that melatonin prevents oxidative stress and death of neurons exposed to A
. In the process of screening indole compounds for neuroprotection against A
, potent neuroprotective properties were
uncovered for an endogenous related species, indole-3-propionic acid
(IPA). This compound has previously been identified in the plasma and
cerebrospinal fluid of humans, but its functions are not known. IPA
completely protected primary neurons and neuroblastoma cells against
oxidative damage and death caused by exposure to A
, by inhibition of
superoxide dismutase, or by treatment with hydrogen peroxide. In
kinetic competition experiments using free radical-trapping agents, the
capacity of IPA to scavenge hydroxyl radicals exceeded that of
melatonin, an indoleamine considered to be the most potent naturally
occurring scavenger of free radicals. In contrast with other
antioxidants, IPA was not converted to reactive intermediates with
pro-oxidant activity. These findings may have therapeutic applications
in a broad range of clinical situations.
 |
INTRODUCTION |
Brains of patients afflicted with Alzheimer's disease show
abnormal expression of numerous oxidative stress indicators (1-5) as
well as extensive evidence of oxidative damage to proteins (6) and
nucleic acids (7, 8). A prominent feature of the Alzheimer's disease
brain is the widespread cerebral deposition of a 40-43-amino acid
peptide called the amyloid
-protein
(A
)1 in the form of
amyloid fibrils within senile plaques and in cerebral and meningeal
blood vessels (9, 10). A large body of data suggests that A
causes
neuronal degeneration and death by mechanisms that involve reactive
oxygen species (Refs. 11-14; reviewed in Ref. 15).
Since the severity of the dementia in Alzheimer's disease has been
correlated best with the extent of synaptic loss and the degree of
neuronal death (16, 17), enhancing neuronal survival has been a primary
objective of many therapeutic strategies. We have recently reported
that melatonin prevents oxidative stress and death of neurons exposed
to the amyloid peptide (18, 19). In the process of screening indole
compounds as neuroprotective agents, new properties were uncovered for
an endogenous species, indole-3-propionic acid (IPA). IPA has
previously been identified in the plasma and cerebrospinal fluid of
humans, but its functions are not known (20, 21). IPA has, like
melatonin, a heterocyclic aromatic ring structure with high resonance
stability, which led us to suspect similar neuroprotective and
antioxidant properties. Here, we report that IPA prevented oxidative
stress and death of primary neurons and neuroblastoma cells exposed to
A
. In addition, IPA also showed a strong level of neuroprotection in
two other paradigms of oxidative stress. We found that the
radical-scavenging efficiency of IPA surpassed the activity of several
previously reported antioxidants, including melatonin, and that in
contrast to many other free radical scavengers, IPA did not generate
pro-oxidant intermediates.
These findings may be relevant to a number of disorders of aging that
are associated with increased oxidative stress. They also raise the
possibility that IPA may be a component of the body's natural defense
against free radical-mediated injury.
 |
EXPERIMENTAL PROCEDURES |
Reagents
All chemicals used in scavenging activity assays were purchased
from Sigma. The indolic acids were dissolved in 0.1 M NaOH; melatonin was dissolved in 0.1 M HCl for the scavenging
assay or prepared as 0.1 M stock as described (19) for the
cytoprotection assays. The solutions were diluted with ultrapure
distilled water, and the pH was adjusted to 7.8 in the scavenging
assay. SK-N-SH human neuroblastoma cells and PC12 rat pheochromocytoma
cells were purchased from the American Tissue Culture Collection
(Manassas, VA) and were maintained in RPMI 1640 medium (Fisher)
supplemented with 10% fetal bovine serum (Life Technologies, Inc.) or
10% horse serum and 5% fetal bovine serum, respectively. E-18 fetal
rat primary hippocampal neurons were obtained from Dr. G. Brewer and grown as described by Brewer et al. (22). Cultures were
maintained in a humidified 5% CO2 incubator. A
-(1-42)
was synthesized at the W. M. Keck Laboratories (Yale University, New
Haven, CT); its purity was evaluated by amino acid sequence and laser
desorption mass spectrometry; and its concentration was calculated by
amino acid analysis (23). A 1 mg/ml stock solution of A
-(1-42) was prepared in 50 mM NaHCO3 (pH 9.6), aliquoted,
lyophilized, and stored at
80 °C until used. Immediately before
the experiments, aliquots of A
-(1-42) were solubilized in distilled
deionized water and diluted to the final concentration in culture
medium. Under these experimental conditions, A
-(1-42) consisted of
a mixture of soluble monomeric/dimeric species, as judged by
polyacrylamide electrophoresis and gel filtration chromatography,
exhibiting a predominant
-structure (2%
-helix, 88%
-sheet,
10% random coil), as determined by circular dichroism analysis as
described (23).
Cell Viability Assays
-Amyloid Neurotoxicity--
The effect of IPA on
A
-mediated neurotoxicity and neuroprotection was tested in E-18
fetal rat primary hippocampal neurons and in SK-N-SH human
neuroblastoma cells. For the experiments using primary neurons,
viability was assessed with the vital fluorescent probe bodipy green
(Molecular Probes, Inc., Eugene, OR) (19) and by the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
reduction method (24). For the experiments involving neuroblastoma
cells, viability was determined by the MTT reduction method and by the
trypan blue exclusion method (19). Different methods were used on
different cell types to ensure that the consistency and reproducibility
of the results were completely independent of the technique and cell
type employed.
For the experiments with bodipy green, control cells (without the
addition of A
) and cells exposed to A
or A
plus IPA or melatonin were incubated with 2 µM bodipy green for 30 min. The cells were scanned for maximum fluorescence via a section
series by scanning laser confocal microscopy (Molecular Dynamics, Inc., Sunnyvale, CA). The images were subjected, as described (19), to
three-dimensional FishNet modeling to obtain relative intensity measurements and section line "cutting" for histogram determination of relative fluorescence intensity levels using Silicon Graphics software. Assessment of cell viability with the MTT reduction assay was
measured by two independent techniques consisting of (a)
direct visualization of staining under a light microscope (25) and
(b) measurement of the optical absorbance of cell lysates using a microplate reader (Bio-Rad) as described (24). For the trypan
blue exclusion method, a minimum of 300 cells/well were counted. All
experiments (for each cell type and for each method) were reproduced
independently in duplicate. Primary hippocampal neurons were allowed to
differentiate for 7-10 days and then treated for 24 h either with
1 µM A
-(1-42) alone or with A
plus either melatonin or IPA. 5-Methoxytryptamine, a related indole compound with
weak hydroxyl radical-scavenging activity (26-28), was used as a
negative control. Neuroblastoma cells were plated in 24-well tissue
culture plates (Nunc, Roskild, Denmark) to an initial 50% density and
allowed to reach 80% confluence prior to treatment.
Lipid Peroxidation Assay--
Using measurements of
malondialdehyde levels, we also examined the effects of IPA on
A
-induced lipid peroxidation, an established indicator of oxidative
toxicity. Lipid peroxidation was measured on PC12 cells exposed to 10 µM A
-(1-42) or 5 mM
diethyldithiocarbamate (DDTC; an inhibitor of superoxide dismutase-1
(29)), alone or in combination with 50 µM melatonin or
indole-3-propionic acid. Cell lysates from two independent triplicate
experiments were collected after the mentioned treatments and used to
measure malondialdehyde levels as described (30).
Oxidative Stress Experiments--
We examined the properties of
IPA in two paradigms of oxidative stress. SK-N-SH human neuroblastoma
cells were exposed to 1 mM DDTC or 50 µM
hydrogen peroxide for 24 h (31), alone or in combination with
different concentrations of melatonin or IPA. The cells were grown as
indicated above for the amyloid toxicity experiments. Cell viability
was assessed by the trypan blue exclusion method. For each form of
oxidative stress, three independent duplicate sets of experiments were conducted.
Hydroxyl Radical Scavenging Assays
Antioxidant Activity--
Hydroxyl radicals were generated
in vitro by hydrogen peroxide exposed to UV light (UV lamp,
Model UV G-11, short-wave UV-254.) The solutions were irradiated
immediately after preparation for 5 min at a distance of 5 cm to
generate hydroxyl radicals by photolysis of hydrogen peroxide (26).
This specific hydroxyl radical-generating system previously allowed the
quantification of the hydroxyl radical-scavenging abilities of
melatonin (26). Melatonin was dissolved as the hydrochloride salt, and
IPA was dissolved as the sodium salt. All incubations were carried out
in 0.1 M glycylglycine buffer (pH 7.8). Using photolysis of
hydrogen peroxide, we reduced the probability of side reactions and
were able to assure that only hydroxyl radical-scavenging activity (not
other nonspecific effects such as metal chelation) was tested here
(26). The spin-trapping agent 5,5-dimethyl-1-pyrroline
N-oxide was used to measure hydroxyl radical adduct
formation by high performance liquid chromatography coupled to an
electrochemical detector (HPLC-ECD) (26). The results were validated by
ESR (26). The fractions containing the hydroxyl radical adduct with the
specific 1:2:2:1 ESR spectrum characteristic for the hydroxyl radical
were quantitated as described previously (26). The hydroxyl
radical-scavenging activity of melatonin and IPA was also measured
using the specific hydroxyl radical-trapping reagent ABTS
(2,2'-azinobis(3-ethylbenzthiazoline-6-sulfonic acid)) (27). In the
presence of highly reactive hydroxyl radicals, ABTS is oxidized to the
stable ABTS cation radical, which can be measured photometrically as
described by Poeggeler et al. (27). The kinetic parameters
and second-order reaction constants were determined as described by
Matuszak et al. (32) and Bors et al. (33).
Pro-oxidant Activity--
To assay for pro-oxidant activity, a
hydroxyl radical-generating system consisting of hydrogen peroxide,
iron, and EDTA was employed. To this end, we incubated the test
compounds and salicylate at a concentration of 0.1 mM in
the presence of 1 mM hydrogen peroxide, 0.1 mM
FeCl3, and 1 mM EDTA. The pro-oxidant activity of compounds depends on the reduction of ferric iron to ferrous iron,
which in turn catalyzes hydroxyl radical generation from hydrogen
peroxide by the Fenton reaction (34). The hydroxyl radical adducts of
salicylate, 2,3-dihydroxybenzoic acid (DHBA) and 2,5-DHBA, were
measured by HPLC-ECD (35).
Oxidation Products of IPA--
We performed pulse radiolysis
with spectrophotometric detection using a 4-MeV van de Graaf
accelerator as described previously (36) to determine the chemical
nature of the 1-electron oxidation product of IPA. The radical-mediated
oxidation of IPA (0.2 mmol dm
3) was monitored at pH 7.8 in 0.1 M phosphate buffer by irradiation of potassium
bromide solutions (0.05 mol dm
3) saturated with
oxygen-free nitrous oxide (N2O; 0.02 mol
dm
3). To test for the metabolite generated upon the
oxidation, IPA was oxidized by incubation of the indole (100 µM) in the presence of hydrogen peroxide (100 µM) and iron sulfate (10 µM) for 30 min on
ice in darkness. The formation of a kynuric acid was measured using a
Model LS50B fluorometer (Perkin-Elmer) at excitation and emission
wavelengths of 360 and 450 nm, respectively. Loss of indole
fluorescence was monitored at excitation and emission wavelengths of
285 and 345 nm, respectively.
 |
RESULTS |
IPA Is Neuroprotective against A
and Other Oxidative
Insults--
The addition of IPA prevented death of primary neurons
and neuroblastoma cells exposed to A
(Figs.
1 and 2). The results obtained with IPA
were extremely consistent in the two cell types used and as indicated
by the different methods employed for assessment of cell survival.
However, 5-methoxytryptamine, a related control indole with weak
scavenging activity, offered no neuroprotection when measured in a
series of parallel experiments (Fig. 1). In the primary rat hippocampal
cultures evaluated by bodipy green fluorescence, 1 µM
A
treatment resulted in almost complete reduction of cell
fluorescence as compared with untreated cells (Fig. 1). In these
experiments, similar concentrations (1 µM) of IPA or melatonin added to A
-containing media were sufficient to provide full protection from the neurotoxic effects of A
, as evidenced by
levels of fluorescence comparable to control primary neurons. With the
MTT reduction method, 1 µM A
was accompanied by a
50-60% reduction of cell viability, suggesting that this method is
less sensitive than the fluorescence technique for detection of
neuronal injury. In qualitative agreement with the results obtained by the bodipy green method, the MTT assay showed that the addition of IPA
along with A
resulted in full protection from amyloid-mediated damage (Fig. 2). No measurable toxicity
of IPA was observed when cells were exposed to IPA alone as evaluated
by either method.

View larger version (98K):
[in this window]
[in a new window]
|
Fig. 1.
Cytoprotection against
A -(1-42) by IPA and melatonin using primary
rat hippocampal neurons. Shown are the results from bodipy green
florescence and confocal laser microscopy. Representative control
hippocampal neurons exhibited high fluorescence levels after incubation
with bodipy green, as shown in A. Upon exposure to
A -(1-42), there was a dramatic decrease in bodipy green
fluorescence throughout the cell population (B). The
addition of melatonin (C) or IPA (D) along with
A -(1-42) totally prevented the changes induced by the peptide
(magnification × 2000). 5-Methoxytryptamine, a control indole
compound, showed no neuroprotective effects (E). Although a
marked degree of neuroprotection was readily apparent, we individually
measured the fluorescence of a minimum of 30 representative cells/well,
and there were no significant differences in fluorescence intensity
between the control and A -(1-42) plus IPA or A -(1-42) plus
melatonin. Pseudocolor scale bar represents fluorescence
intensity values.
|
|

View larger version (138K):
[in this window]
[in a new window]
|
Fig. 2.
Cytoprotection against
A -(1-42) by IPA and melatonin using primary
rat hippocampal neurons. Shown are the results obtained with the
MTT reduction method under light microscopy. Over 95% control
hippocampal neurons stained dark after incubation with the formazan
step of the MTT reduction method (A). Upon exposure to
A -(1-42), there was a striking decrease in staining in >50% of
the neurons (B). The addition of melatonin (D) or
IPA (F) along with A -(1-42) totally protected the
changes induced by the peptide alone, as demonstrated by a similar
number of darkly staining cells and the degree of staining intensity.
5-Methoxytryptamine exhibited no neuroprotective effect (not shown). No
cytotoxicity of melatonin or IPA was observed when the neurons were
exposed to these compounds alone (C and E)
(magnification × 400).
|
|
Similar results were obtained in SK-N-SH neuroblastoma cells. IPA fully
protected these cells against A
-(1-42)-mediated neurotoxicity, as
assessed by the trypan blue method (Fig.
3) and the MTT reduction assay (data not
shown). In agreement with our previous studies (19), melatonin also
demonstrated potent neuroprotective properties.

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 3.
Confirmatory neuroprotection studies by IPA
and melatonin against A toxicity on SK-N-SH
human neuroblastoma cells. Shown are the results obtained with the
trypan blue exclusion method. Results from these studies were extremely
consistent and in agreement with the experiments on primary neurons.
A -(1-42) neurotoxicity was dose-dependent and
completely prevented by IPA and melatonin. The bar graph and
lines represent the means ± S.D., respectively, of
three independent duplicate experiments. A minimum of 300 cells/well
were counted.
|
|
IPA was also effective in preventing lipid peroxidation induced either
by A
or by DDTC. In these experiments, we used PC12 rat
pheochromocytoma cells because we found the levels of lipid peroxidation induced in these cells to be more consistent than in other
cell lines (19). As indicated in Fig. 4,
when IPA was added to the cells along with A
or DDTC, there was
marked reduction of lipid peroxidation.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 4.
IPA and melatonin protect PC12 cells against
oxidative stress induced by A -(1-42) or
DDTC. Shown are the results obtained with the malondialdehyde
assay for lipid peroxidation. The bar graph shows the
means ± S.E. for each treatment, as indicated, of two independent
triplicate experiments. Both IPA and melatonin were effective in
preventing lipid peroxidation.
|
|
As shown in Fig. 5 (A and
B), IPA also prevented death of neuroblastoma cells mediated
either by exposure to DDTC or by treatment with
H2O2. Neither DDTC nor
H2O2 is a free radical, but both lead directly
or indirectly to increased production of other reactive radicals
(i.e. hydroxyl, peroxynitrite), causing oxidative damage within cells (reviewed in Ref. 37). Dose-response studies showed that
the neuroprotective activity of IPA exceeded that of melatonin by
~10-fold when DDTC was used to induce oxidative stress and by
~5-fold when H2O2 was the oxidative agent, as
measured by the trypan blue exclusion method (Fig. 5, A and
B).

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 5.
Dose-response studies of IPA and melatonin as
a function of cell viability of SK-H-SH neuroblastoma cells
exposed to DDTC (A) or hydrogen peroxide
(B). Shown are the results obtained with the
trypan blue exclusion method. The bar graphs depict the
means ± S.D. of three independent duplicate experiments. Note
that with the concentrations used, a maximum level of neuroprotection
with IPA was reached at 10 µM for either modality of
injury. For melatonin, full neuroprotection was observed at 100 µM for DDTC and at 50 µM for hydrogen
peroxide with this assay.
|
|
IPA Is a Potent Hydroxyl Radical Scavenger--
In kinetic
competition studies, melatonin and IPA reacted with hydroxyl radicals
at a diffusion-controlled rate, yielding reaction constants of 4 and
8 × 1010 mol liter
1 s
1,
respectively, in both assay systems. As shown in Fig.
6 (A and B), IPA
exhibited marked hydroxyl radical-scavenging efficiency, which exceeded
the capacity of melatonin on an equimolar basis. In addition, the
radical-scavenging capacity of IPA surpassed the efficiencies reported
for other structurally related (i.e. indole-3-acetic acid)
and unrelated (i.e. trolox) antioxidants by at
least an order of magnitude (26, 27, 38).

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 6.
Hydroxyl radical-scavenging activity of IPA
and melatonin. Shown are the results obtained with the
5,5-dimethyl-1-pyrroline N-oxide method (A) and
the ABTS method (B). Inhibition of 5,5-dimethyl-1-pyrroline
N-oxide-hydroxyl radical adduct formation by IPA and
melatonin is shown in A as the means ± S.E. of three
independent triplicate experiments. Inhibition of ABTS cation radical
formation by IPA and melatonin is shown in B (three
independent triplicate experiments). , melatonin; ,
indole-3-propionic acid.
|
|
IPA Does Not Form Pro-oxidant Intermediates--
In contrast to
other potent hydroxyl radical scavengers, including the structurally
similar indole compounds indole-3-acetic acid and indole-3-pyruvic
acid, we found that IPA was not converted to reactive pro-oxidant
intermediates (Table I). On the other hand, ascorbate (vitamin C), trolox (a water-soluble analogue of
vitamin E), and glutathione were highly pro-oxidant, as shown in Table
I. These antioxidants and the indolic acids indole-3-acetic acid and
indole-3-pyruvic acid increased hydroxyl radical generation in the presence of oxidized iron and thereby promoted
hydroxyl radical adduct formation catalyzed by this transition metal
(Table I). The measured pro-oxidant properties of the mentioned
compounds are in agreement with previously published results (34, 39). Our results showed that 12 µs after pulse radiolysis of
N2O-saturated potassium bromide, solutions containing IPA
generated the respective indolyl cation radical, characterized by an
absorption band centered at 570 nm (
= 2400 dm3
mol
1 cm
1) and another band at 360 nm
(
= 4800 dm3 mol
1 cm
1).
Fluorometric measurements demonstrated a complete loss of indole fluorescence (excitation and emission wavelengths of 280 and 360 nm,
respectively) with the formation of an oxidation product with excitation and emission maxima characteristic for a kynuric acid (excitation and emission wavelengths of 360 and 450 nm,
respectively).
View this table:
[in this window]
[in a new window]
|
Table I
Pro-oxidant activities of several agents as evaluated by formation of
2,3- and 2,5-DHBA, an indicator of OH radical formation
The test compounds and salicylate were incubated at a concentration of
0.1 mM in the presence of 1 mM hydrogen
peroxide, 0.1 mM FeCl3 and 1 mM EDTA.
The hydroxyl radical adducts of salicylate, 2,3-DHBA, and 2,5-DHBA were
measured by HPLC-ECD. The measurements are expressed as a percentage of
control and represent the means ± S.D. from six independent
experiments.
|
|
 |
DISCUSSION |
Two main lines of investigation have now converged to suggest that
A
causes extensive degeneration and death of neurons by mechanisms
that involve reactive oxygen species. One line of evidence is the
identification of oxidative markers that co-localize within the amyloid
deposits in Alzheimer's disease brain (1, 2) and in transgenic
Alzheimer's disease mice (13, 14). A second, but equally important,
body of data demonstrates that oxygen free radicals are produced upon
exposure of cells to A
.
It has been recently shown that A
-mediated toxicity can be prevented
by several endogenous free radical scavengers such as melatonin (18,
19) and
-tocopherol (43). The recently established neuroprotective
and antioxidant properties of melatonin suggested to us that other
similar compounds may share some of these features. In this study, we
showed that IPA protected neuronal cells against oxidative stress and
death mediated by A
, and these effects were consistent and
reproducible in several paradigms of oxidation. The free
radical-scavenging properties of IPA surpassed those of melatonin, the
most powerful known natural hydroxyl radical scavenger (29, 37, 38).
Antioxidant activities were evident in various paradigms, which
included measurements of lipid peroxidation (Fig. 4), superoxide
dismutase inhibition (Fig. 5A), treatment with hydrogen
peroxide (Fig. 5B), and kinetic competition studies (Fig. 6,
A and B). These findings may have therapeutic
relevance to Alzheimer's disease, a condition characterized by a
pervasive level of oxidative stress.
The chemical structures and the scavenging mechanisms of melatonin and
IPA show no similarities to the common chain-breaking phenolic
antioxidants such as vitamin E (44). Vitamin E possesses a reactive
hydroxyl group, which enables it to donate a hydrogen atom, thereby
reducing free radicals that promote radical chain reactions such as
peroxyl radicals. However, because of their high reactivity,
chain-breaking antioxidants such as vitamin E autoxidize in the
presence of transition metals and increase the formation of
primary radicals such as hydroxyl radicals (34). In contrast, melatonin
and IPA do not undergo autoxidation in the presence of transition
metals and are endogenous electron donors that primarily detoxify
hydroxyl radicals (which are the initiators of radical chain
reactions.) Of all oxygen-derived free radicals, hydroxyl radicals are
the most reactive.
Like melatonin, IPA is also found in plasma and cerebrospinal fluid
under physiological conditions (20, 21). IPA is produced by deamination
of L-tryptophan by commensal bacteria in human and animal
intestines (45), although its production by other tissues has not been
systematically investigated. The lack of pro-oxidant effects is perhaps
the most important feature of IPA, which, as mentioned, is shared only
by melatonin (28, 38). In contrast, significant enhancement of
iron-mediated formation of hydroxyl radicals was found when we explored
the reactions catalyzed by glutathione, trolox, ascorbic acid, and
selected indoles, in agreement with a previous study (34). It has also been demonstrated that under certain conditions, hydroxylated indoleamines such as N-acetylserotonin and
6-hydroxymelatonin or related indolyl acids such as indole-3-acetic
acid can exhibit potent pro-oxidant properties (32, 39), although
cytoprotective antioxidant activity has recently been claimed for these
compounds (46). In the case of indole-3-acetic acid and related
congeners, the formation of these pro-oxidant species appears to be
dependent on the generation of reactive peroxyl radicals upon
decarboxylation of the side chain and the addition of oxygen to a
skatole (indole-3-methyl) radical (39). Although the presence of an
electron-rich aromatic ring system in IPA allows the detoxification of
highly reactive radicals by electron donation (Fig.
7), its side chain cannot be
decarboxylated (39), and thus, unlike other indoles, it cannot be
converted to a reactive pro-oxidant intermediate. Our results showed
that IPA was completely devoid of any pro-oxidant activity (Table I).
These properties make IPA and melatonin far superior to many other
antioxidant compounds such vitamin E. In addition, these indoles are
not cytotoxic, and in contrast to synthetic antioxidants, they are
present in the body under physiological conditions.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 7.
Hydroxyl radical-mediated oxidation of
IPA. Shown is the formation of a kynuric acid by the
radical-mediated oxidation of IPA. IPA reacts with the hydroxyl
radical, reducing this reactive oxygen species by electron donation to
a hydroxyl anion. The indolyl cation radical in turn reacts with the
superoxide anion radical and is oxidized to a kynuric acid.
|
|
Melatonin is a hydroxyl radical scavenger with a rate constant 3 orders
of magnitude higher than that exhibited by chain-breaking antioxidants
such as vitamin E. We demonstrate here that IPA is at least twice as
potent as melatonin, making this compound the most effective hydroxyl
radical scavenger detected to date. Because hydroxyl radicals cannot be
enzymatically detoxified, radical-scavenging compounds have evolved
early in life phylogeny to provide on-site protection against these
reactive radicals. The physiological functions of IPA are not known,
although it is intriguing to speculate on a protective role of this
substance against oxidative stress. Additional studies must be
conducted to explore this possibility. Interestingly, circulating serum
levels of IPA also exceed those of melatonin. Future studies should
also determine whether changes in endogenous IPA levels correlate with
certain disorders in which free radicals may be implicated.
 |
ACKNOWLEDGEMENTS |
Dr. Gregory Brewer (University of Southern
Illinois) provided the primary neurons, and Dr. Raymond Hester assisted
with the confocal laser studies.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants R55 AG14381, RO1 AG11130, RO1 AG05891, and RO1 AG08721.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Both authors contributed equally to this work.

To whom correspondence should be addressed: University of South
Alabama, College of Medicine, Mobile, AL 36617. Tel.: 334-471-7804; Fax: 334-471-7838; E-mail: mpappoll@usamail.usouthal.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
A
, amyloid
-protein;
IPA, indole-3-propionic acid;
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide;
HPLC-ECD, high performance liquid chromatography coupled to an electrochemical
detector;
DDTC, diethyldithiocarbamate;
DHBA, dihydroxybenzoic
acid.
 |
REFERENCES |
| 1.
|
Pappolla, M. A.,
Omar, R. A.,
Kim, K. S.,
and Robakis, N. K.
(1992)
Am. J. Pathol.
140,
621-628[Abstract]
|
| 2.
|
Smith, M. A.,
Kutty, R. K.,
Richey, P. L.,
Yan, S.-D.,
Stern, D.,
Chader, G. J.,
Wiggert, B.,
Petersen, R. B.,
and Perry, G.
(1994)
Am. J. Pathol.
145,
42-47[Abstract]
|
| 3.
|
Aksenov, M. Y.,
Aksenova, M. V.,
Markesbery, W. R.,
and Butterfield, D. A.
(1998)
J. Mol. Neurosci.
10,
181-192[Medline]
[Order article via Infotrieve]
|
| 4.
|
Sayre, L. M.,
Zelasko, D. A.,
Harris, P. L.,
Perry, G.,
Salomon, R. G.,
and Smith, M. A.
(1997)
J. Neurochem.
68,
2092-2097[Medline]
[Order article via Infotrieve]
|
| 5.
|
Calingasan, N. Y.,
Uchida, K.,
and Gibson, G. E.
(1999)
J. Neurochem.
72,
751-756[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Smith, C. D.,
Carney, J. M.,
Starke-Reed, P. E.,
Oliver, C. N.,
Stadtman, E. R.,
Floyd, R. A.,
and Markesberry, W. R.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
10540-10543[Abstract/Free Full Text]
|
| 7.
|
Lyras, L.,
Cairns, N. J.,
Jenner, A.,
Jenner, P.,
and Halliwell, B.
(1997)
J. Neurochem.
68,
2061-2069[Medline]
[Order article via Infotrieve]
|
| 8.
|
Mecocci, P.,
MacGarvey, U.,
and Beal, M. F.
(1994)
Ann. Neurol.
36,
747-751[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Glenner, G. G.,
and Wong, C. W.
(1984)
Biochem. Biophys. Res. Commun.
120,
885-890[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Masters, C. L.,
Simms, G.,
Weinman, N. A.,
Multhaup, G.,
McDonald, B. L.,
and Beyreuther, K.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
4245-4249[Abstract/Free Full Text]
|
| 11.
|
Behl, C.,
Davis, J. B.,
Lesley, R.,
and Schubert, D.
(1994)
Cell
77,
817-827[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
| Goodman, Y., and Mattson, M. P. (1994) Exp. Neurol.
128, 1-12
|
| 13.
|
Pappolla, M. A.,
Chyan, Y.-J.,
Omar, R. A.,
Hsiao, K.,
Perry, G.,
Smith, M. A.,
and Bozner, P.
(1998)
Am. J. Pathol.
152,
871-877[Abstract]
|
| 14.
|
Smith, M. A.,
Hirai, K.,
Hsiao, K.,
Pappolla, M. A.,
Harris, P. L. R.,
Siedlak, S. L.,
Tabaton, M.,
and Perry, G.
(1998)
J. Neurochem.
70,
2212-2215[Medline]
[Order article via Infotrieve]
|
| 15.
|
Mattson, M. P.
(1997)
Alzheimer's Dis. Rev.
2,
1-14
|
| 16.
|
Terry, R. D.,
Masliah, E.,
Salmon, D. P.,
Butters, N.,
DeTeresa, R.,
Hill, R.,
Hansen, L. A.,
and Katzman, R.
(1991)
Ann. Neurol.
30,
572-580[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Hyman, B. T.,
West, H. L.,
Gomez-Isla, T.,
and Mui, S.
(1995)
in
Research Advances in Alzheimer's Disease and Related Disorders
(Iqbal, K.
, Mortimer, J. A.
, Winblad, B.
, and Wieniewski, H. M., eds)
, pp. 453-480, John Wiley & Sons, Inc., New York
|
| 18.
|
Bozner, P.,
Grishko, V.,
LeDoux, S. P.,
Wilson, G. L.,
Chyan, Y.-C.,
and Pappolla, M. A.
(1997)
J. Neuropathol. Exp. Neurol.
56,
1356-1362[Medline]
[Order article via Infotrieve]
|
| 19.
|
Pappolla, M. A.,
Sos, M.,
Omar, R. A.,
Bick, R. J.,
Hickson-Bick, D. L. M.,
Reiter, R. J.,
Efthimiopoulos, S.,
and Robakis, N. K.
(1997)
J. Neurosci.
17,
1683-1690[Abstract/Free Full Text]
|
| 20.
|
Young, S. N.,
Anderson, G. M.,
Gauthier, S.,
and Purdy, W. C.
(1980)
J. Neurochem.
34,
1087-1092[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Morita, I.,
Kawamoto, M.,
and Yoshiba, H.
(1992)
J. Chromatogr.
576,
334-339[Medline]
[Order article via Infotrieve]
|
| 22.
|
Brewer, G. J.,
Torricelli, J. R.,
Evege, E. K.,
and Price, P. J.
(1993)
J. Neurosci. Res.
35,
567-576[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Pappolla, M.,
Bozner, P.,
Soto, C.,
Shao, H.,
Robakis, N. K.,
Zagorski, M.,
Frangione, B.,
and Ghiso, J.
(1998)
J. Biol. Chem.
273,
7185-7188[Abstract/Free Full Text]
|
| 24.
|
Hansen, M. B.,
Nielsen, S. E.,
and Berg, K.
(1989)
J. Immunol. Methods
119,
203-210[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Mattson, M. P.,
Cheng, B.,
Davis, D.,
Bryant, K.,
Lieberburg, I.,
and Rydel, R. E.
(1992)
J. Neurosci.
12,
376-389[Abstract]
|
| 26.
|
Tan, D.-X.,
Chen, L.-D.,
Poeggeler, B.,
Manchester, L. C.,
and Reiter, R. J.
(1993)
Endocrinol. Jpn.
1,
57-60
|
| 27.
|
Poeggeler, B.,
Reiter, R. J.,
Hardeland, R.,
Tan, D.-X.,
and Barlow-Walden, L. R.
(1996)
Redox Rep.
2,
179-184
|
| 28.
|
Chan, T.-Y.,
and Tang, P.-L.
(1996)
J. Pineal Res.
20,
187-191[Medline]
[Order article via Infotrieve]
|
| 29.
|
Frank, L.,
Wood, D.,
and Robert, R.
(1987)
Biochem. Pharmacol.
27,
251-254
|
| 30.
|
Omar, R. A.,
Yano, S.,
and Kikkawa, Y.
(1987)
Cancer Res.
47,
3473-3476[Abstract/Free Full Text]
|
| 31.
|
Whittemore, E. R.,
Loo, D. T.,
and Cotman, C. W.
(1994)
Neuroreport
5,
1485-1488[Medline]
[Order article via Infotrieve]
|
| 32.
|
Matuszak, Z.,
Reszka, K. J.,
and Chignell, C. F.
(1996)
Free Radical Biol. Med.
23,
367-372
|
| 33.
|
Bors, W.,
Michel, C.,
and Saran, M.
(1985)
in
CRC Handbook of Methods for Oxygen Radical Research
(Greenwald, R. A., ed)
, pp. 181-188, CRC Press, Inc., Boca Raton, FL
|
| 34.
|
Nappi, A. J.,
and Vass, E.
(1997)
Biochim. Biophys. Acta
1336,
295-302[Medline]
[Order article via Infotrieve]
|
| 35.
|
McCabe, D. R.,
Maher, T. J.,
and Acworth, I. N.
(1997)
J. Chromatogr.
691,
23-32
|
| 36.
|
Candeias, L. P.,
Everett, S. A.,
and Wardman, P.
(1993)
Free Radical Biol. Med.
15,
385-394[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Reiter, R. J.
(1998)
Prog. Neurobiol.
56,
359-384[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Poeggeler, B.,
Reiter, R. J.,
Tan, D.-X.,
Chen, L.-D.,
and Manchester, L. C.
(1993)
J. Pineal Res.
14,
151-168[Medline]
[Order article via Infotrieve]
|
| 39.
|
Candeias, L. P.,
Folkes, L. K.,
Rorssa, M.,
Parrick, P.,
and Wardman, P.
(1995)
Free Radical Res.
23,
403-418[Medline]
[Order article via Infotrieve]
|
| 40.
| Deleted in proof
|
| 41.
| Deleted in proof
|
| 42.
| Deleted in proof
|
| 43.
|
Behl, C.,
Davis, J.,
Cole, G. M.,
and Schubert, D.
(1992)
Biochem. Biophys. Res. Commun.
186,
944-950[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Poeggeler, B.
(1998)
in
Reactive Oxygen Species in Biology Systems: An Interdisciplinary Approach
(Gibbons, D. L.
, and Colton, C. D., eds)
, pp. 421-451, Plenum Press, New York
|
| 45.
|
Jellet, J. J.,
Forrest, T. P.,
MacDonald, A.,
and Marrie, T. J.
(1980)
Can. J. Microbiol.
26,
448-453[Medline]
[Order article via Infotrieve]
|
| 46.
|
Moosmann, B.,
Uhr, M.,
and Behl, C.
(1997)
FEBS Lett.
413,
467-472[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.